Patents by Inventor James Haseloff

James Haseloff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6071730
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 6, 2000
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 6015794
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 18, 2000
    Assignee: The General Hospital Corporation
    Inventors: James Haseloff, Howard M. Goodman
  • Patent number: 6010904
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 4, 2000
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5882907
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 16, 1999
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5874414
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: November 17, 1993
    Date of Patent: February 23, 1999
    Assignee: The General Hospital Corporation
    Inventors: James Haseloff, Howard M. Goodman
  • Patent number: 5866384
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 2, 1999
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5863774
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 26, 1999
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5849548
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 15, 1998
    Assignees: The General Hospital Corporation, The President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman
  • Patent number: 5641673
    Abstract: The design of new ribozymes capable of self-catalyzed trans-splicing which are base a upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3' exon sequence into any chosen target RNA sequence in a highly precise manner. A method of cell ablation is also described that provides a toxic product to a host cell in vivo in a targetted, regulated manner utilizing novel trans-splicing ribozymes of the invention. Inactive pro-ribozyme forms are also described.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: June 24, 1997
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: James Haseloff, Andrea Brand, Norbert Perrimon, Howard M. Goodman